Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
Given the frequent coexistence of obesity and T2D with cardiovascular disease and chronic kidney disease (CKD), incretin-based therapies (encompassing selective GLP-1 and multi-receptor agonists) have emerged as disease-modifying treatments across the cardiovascularkidneymetabolic (CKM) spectrum
Certain conditions, such as a history of thyroid cancer or pancreatitis, may make treatment unsuitable
Meanwhile, employers are still grappling with unknowns associated with GLP-1 drugs, namely side effects and still-emerging long-term clinical studies, and the effectiveness of cost control tools like prior authorization and step therapy. But as evidence of the benefits of using the drugs for weight loss continues to grow, along with increased employee demand, it looks like many employers might add coverage
The upregulation of genes associated with skin abnormalities, neurodevelopmental disruptions, liver dysfunction, and lung pathology suggests that maternal GLP-1 exposure may lead to significant adverse outcomes for offspring health
C., Allebeck, P
